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A R T I C L E   I N F O A B S T R A C T 
New oral anticoagulant agents continue to emerge on the market and their safety 
requires assessment to provide evidence of their suitability for clinical use. There-
fore, we searched standard databases to summarize the English language literature 
on medicine-related problems (MRPs) of direct oral anticoagulants DOACs 
(dabigtran, rivaroxban, apixban, and edoxban) in the treatment of adults with atri-
al fibrillation. Electronic databases including Medline, Embase, International 
Pharmaceutical Abstract (IPA), Scopus, CINAHL, the Web of Science and 
Cochrane were searched from 2008 through 2016 for original articles. Studies pub-
lished in English reporting MRPs of DOACs in adult patients with AF were in-
cluded. Seventeen studies were identified using standardized protocols, and two 
reviewers serially abstracted data from each article. Most articles were inconclusive 
on major safety end points including major bleeding. Data on major safety end 
points were combined with efficacy. Most studies inconsistently reported adverse 
drug reactions and not adverse events or medication error, and no definitions were 
consistent across studies. Some harmful drug effects were not assessed in studies 
and may have been overlooked. Little evidence is provided on MRPs of DOACs in 
patients with AF and, therefore, further studies are needed to establish the safety 
of DOACs in real-life clinical practice. 
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INTRODUCTION 
The identification, resolution, and prevention of 
medicine-related problems (MRPs) has been de-
scribed as an essential process of pharmaceutical 
care, where pharmacists and other health care pro-
fessionals as well as patients work together to 
achieve improved therapeutic outcomes and quality 
of life (Basger et al., 2015). According to the Pharma-
ceutical Care Network Europe, an MRP can be de-
fined as “an event or circumstance involving drug 
therapy that actually or potentially interferes with 
desired health outcomes”. This includes therapeutic 
failure, patient behaviour, adherence to the medica-
tion, and inappropriate drug use. These may set off 
or comprise risk factors leading to medication errors 
(MEs) and adverse drug reactions/events 
(ADRs/ADEs), which could affect patient health 
outcome. An ME is a preventable event that actually 
or can potentially lead to inappropriate drug use or 
injury to the patient when the medication is in the 
hands of a healthcare professional or patient (the Na-
tional Coordinating Council for Medication Error 
Reporting and Prevention [NCC MERP], 2015). 
ADRs are harmful, unintended, undesired, or exces-
sive responses to a drug, occurring at normal doses 
in the diagnosis or therapy of a disease or for the res-
toration or correction of a physiological function, 
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whose causality has been known (Hughes and 
Blegen, 2008). ADEs are injuries resulting from the 
use of a medicinal product, although the causality of 
the relationship has not been determined (Strand et 
al., 1990).  
Cardiovascular diseases (CVDs) are the major causes 
of mortality, contributing to approximately 31% of 
deaths globally (World Health Organisation WHO, 
2015) and in the UK, this figure is estimated to be 
25% of deaths (British Heart Foundation BHF, 2015). 
Of all the CVDs, atrial fibrillation (AF) is the most 
common, affecting approximately 1.5–2% of the 
population worldwide (Camm et al., 2012). The pres-
ence of AF is associated with a five times higher risk 
of stroke and three times higher risk of heart failure 
(Camm et al., 2012). Anticoagulant therapy is a pre-
requisite to avoiding stroke and systemic embolism 
in patients with AF. The clinical use of oral anticoag-
ulants began in 1954 after the approval of warfarin, 
which is a vitamin K antagonist (Plovanich and Mo-
staghimi, 2015). For more than half a century, warfa-
rin was the only available oral anticoagulant (Bauer, 
2013). Although, new categories of anticoagulant 
drugs were developed and labelled as novel oral an-
ticoagulants, new oral anticoagulants, non-vitamin K 
antagonist oral anticoagulants (NOACs), and direct 
oral anticoagulants (DOACs) to be used in clinical 
practice targeted at overcoming the disadvantage of 
warfarin. The DOACs have four important pharma-
cological properties: a rapid onset and offset of ac-
tion, predictable therapeutic effect, fewer drug-drug 
interactions, and absence of food interactions (Bauer, 
2013; Mekaj et al., 2015). These properties provide 
them with important advantages over traditional 
oral vitamin K antagonists such as warfarin 
(Plovanich and Mostaghimi, 2015). Since 2008, the 
European Medicine Agency (EMA) and the US Food 
and Drug Administration (FDA) have approved the 
clinical use of DOACs such as dabigatran, rivaroxa-
ban, apixaban, and edoxaban in the European Union 
(EU) and worldwide (Mekaj et al., 2015). In the UK, 
the National Institute for Health and Care Excellence 
(NICE) approved dabigatran in 2012, rivaroxaban 
and apixaban in 2013, and edoxaban in 2015 for the 
prevention of stroke and systemic embolism in non-
valvular AF (NVAF) (National Institute for Health 
and Care Excellence NICE, 2015). Following the offi-
cial approval of DOACs, their use has also increased 
leading to 1,091,000 prescriptions in England by 
2014. Moreover, numerous studies from different 
countries worldwide arrived at the same conclusion 
that anticoagulants represent a high-risk medication 
and are a threat to patient safety (Saedder et al., 
2014). However, only limited studies examining the 
MRPs of new oral anticoagulants have been carried 
out in real world clinical practice (Donaldson and 
Norbeck, 2013). 
Furthermore, anticoagulant-related bleeding is com-
mon and often serious (Landefeld and Beyth, 1993; 
Crowther and Warkentin, 2008). Hence, several me-
ta-analyses of phase III RCTs trials have indicated 
that the DOACs are as safe and efficient as VKAs in 
preventing and treating thromboembolic events es-
pecially in patients diagnosed with non-valvular AF 
(Caldeira et al., 2015a; Sardar et al., 2015; Scridon and 
Constantin, 2015).  
The DOACs have improved the safety of anticoagu-
lation by reducing intracranial haemorrhage, which 
is a fatal type of bleeding caused by anticoagulants 
(Caldeira et al., 2015a). The DOACs also reduce the 
risk of ischemic stroke, major bleeding, myocardial 
infarction, and mortality (Caldeira et al., 2015b). Alt-
hough clinical trial data shows a similar ADR profile, 
there is considerably less knowledge about how this 
happens in real life setting such as in a secondary 
care setting or an anticoagulant clinic. 
Therefore, a systematic review of published studies 
on the nature and severity of MRPs in adult patients 
using DOACs was performed. The aim of this review 
was to investigate the prevalence, categories, severi-
ty, and possible contributing factors of MRPs among 
adult patients with AF using DOACs reported in the 
literature. 
MATERIALS AND METHODS 
Search Strategy  
The following electronic databases were searched by 
HA: Medline, Embase, International Pharmaceutical 
Abstract (IPA), Scopus, CINAHL, Cochrane Library, 
and Web of Science from January 2008 to July 2016. 
To increase the likelihood of identifying additional 
relevant studies, the reference lists of included stud-
ies and relevant review articles were hand searched.  
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In searching databases, a combination of free text-
words and Medical Subject Heading (MeSH) was 
used to ensure a comprehensive search of the litera-
ture. In addition, synonyms and additional terms 
were used and truncation symbols such as the aster-
isk (*) were used. Boolean terms `OR’ and `AND’ 
were used to broaden and narrow down the search, 
respectively.  
The search commenced with two main keywords: 
medicine-related problem and new oral anticoagu-
lant. The search used medicine-related problem as a 
keyword and a number of terms that described prob-
lems related to the use of medication such as drug-
related problem. Additional list search terms were 
generated by going over the literature that was re-
viewed using medicine-related problem as a key-
word (Van Mil et al., 2004; Van den Bemt and Eg-
berts, 2007; Alhomoud et al., 2012; Adusumilli and 
Adepu, 2014; Al Hamid et al., 2014). Each article 
suggested a list of search terms for ‘medicine-related 
problem’. The different keywords used to search for 
relevant articles in this review are presented in Table 
1. The search terms and the synonyms were linked 
using the Boolean operator ‘AND’ or ‘OR’ to arrive at 
the final number of articles titles and abstracts that 
were reviewed in detail. 
Following the conclusion of all database searches, 
duplicate citations were identified and excluded us-
ing a reference management software (Mendeley, 
Elsevier 2016 Mendeley Ltd) and manual title exami-
nation. 
Inclusion and Exclusion Criteria  
For this review, the inclusion criteria were studies 
focused on adults ≥ 18 years with AF, those concern-
ing medicine-related problems of DOACs, original 
studies using quantitative or mixed methodology, 
and those conducted in a clinical setting. Studies 
published in English between 2008 and 2016 were 
included. The researchers excluded studies related to 
drug abuse and misuse. Conference abstract, re-
views, opinions, and editorial papers were also ex-
cluded. Case reports were not included in this review 
because they depended on specific cases. 
Table 1. Search terms used in this review. 
Search  Keywords - Use of Boolean 
Search 
 
1.Medicine-
related problem 
OR Medication related problem  
Medicine related morbidity  
Medication-therapy problems 
Drug related problem 
Drug related morbidity 
Drug induced problem 
Drug therapy problem 
Drug management problem  
Therapy-related problems 
Treatment related problem 
Pharmaceutical care issue 
Drug safety 
Adverse drug reaction 
Adverse drug event 
Medication error 
Medication adherence  
Medication compliance 
Non-compliance 
 
2. Direct oral 
anticoagulant 
OR Novel oral anticoagulant 
Non-vitamin K antagonist 
anticoagulant  
New oral anticoagulant  
Dabigatran  
Rivaroxaban 
Apixaban 
Edoxaban 
NOACs  
DOACs  
3.   ‘1’ AND ‘2’   
 
Data Extraction and Quality Assessment  
Data extraction from the retrieved studies was car-
ried out by the first author of this paper (HA) using 
standardized forms to extract data consisting of the 
following information: study type, country, settings, 
population age, duration, sample size, types of 
MRPs, and reported severe cases. The use of stand-
ardized data extraction forms can provide consisten-
cy, reduce bias, and improve the validity of the re-
view. The data were reviewed independently by an-
other reviewer (ZA). The screening process was car-
ried out systematically and included the titles, ab-
stracts, and full articles. Once the inclu-
sion/exclusion criteria were applied, a third review-
er (NU) verified the data. For studies that included 
all anticoagulant drugs, only data for DOACs were 
included. 
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Table 2. Summary of Studies 
No. Study 
 
Country Setting Study Design Population Duration  Sample Size Prevalence Rate 
of Bleeding ADR 
(%) 
Prevalence Rate of 
Non-Bleeding 
ADR (%) 
Reported 
Severe Cas-
es (%) 
Main Findings Other 
1. Larsen et al. 
(2013) 
Denmark National registry Retrospective 
cohort  
Patients with 
AF 
10.5 
months 
13,914 HR Intracranial 
bleeding 0.24, 
95% CI: 0.08-0.56; 
GIB 0.60, 95% CI: 
0.37 to 0.93 
NR NR No evidence of excessive intracranial 
and gastrointestinal bleeding events 
for Dabigatran treated patients com-
pared with Warfarin 
 
2. Lee, Han and 
Miyahara 
(2013) 
US Pharmacy-
managed antico-
agulation clinic 
Retrospective 
cohort  
Patients on 
Dabigatran 
3 
months 
68 NR NR NR Adherence of Dabigatran does not 
significantly differ between patients 
followed by pharmacy-managed clinic 
and those followed by usual care. 
Adherence 
Pharmacy-
managed 
93.1%, usual 
care 88.3% 
3. Cutler et al. 
(2014) 
US University of 
California Davis 
Medical Centre 
Retrospective 
descriptive  
Patients with 
AF 
12 
months 
159 NR NR 5 patients 
hospitalised 
(5/159=3.14
%) 
There is need for improved Dabigatran 
adherence monitoring and follow-up 
43.4% non-
adherent to 
Dabigatran 
therapy 
4. Graham et al. 
(2014) 
US Medicare Data-
base 
Retrospective 
cohort  
Medicare 
patients with 
AF 
27 
months 
134,414 2.2% 0.04% NR Dabigatran has increased risk of major 
gastrointestinal bleeding than Warfarin 
on elderly NVAF patients 
 
5. Andreica and 
Grissinger 
(2015) 
US Pennsylvania 
Patient Reporting 
System 
Retrospective  Medication 
errors 
12 
months 
NA NR NR NR Extra precaution and risk-reduction 
strategies are needed to reduce medi-
cation errors related to NOACs 
831 medica-
tion errors 
6. Chang et al. 
(2015) 
US Database of 
commercially 
insured 
Retrospective 
cohort  
Commercial-
ly insured 
population 
18 
months 
46,163 HR (Dabigatran 
1.2 95% CI 0.96 to 
1.53) Rivaroxaban 
(0.98, 95%, CI 
0.36-2.69) 
NR NR No statistical differences in gastrointes-
tinal bleeding between Dabigatran and 
Rivaroxaban, and Warfarin but cannot 
rule out more than 50% and two-fold 
higher risk of Dabigatran and Rivarox-
aban compared to Warfarin.  
 
7. Forslund, 
Wettermark 
and Hjemdahl 
(2016) 
Sweden Administrative 
health data regis-
ter 
Retrospective 
cohort  
Patients with 
NVAF 
32 
months 
20,636 NR NR NR Persistence for NOACs decreased 
slightly from 88.2% in year 1 to 82.9% 
in year 2.  
Persistence 
88.2% (year 1) 
and 82.9% 
(year 2) 
8. Nishtala et al. 
(2016) 
New Zea-
land 
Population-level 
data 
Retrospective 
cohort 
Patients with 
NVAF 
18 
months 
9,220 HR (0.45 (0.37–
0.55) any haemor-
rhage 
NR NR Dabigatran has lower risk for 
any/intra-cerebral haemorrhaging 
compared to Warfarin 
 
9. Donaldson 
and Norbeck 
(2008) 
US Pharmacy man-
aged out-patient 
clinic 
Prospective 
cohort 
Out-patients 18 
months 
221 4.07% (9/221) 2.7% (6/221) NR Pharmacists should monitor Patients 
on Dabigatran for complications to 
determine compliance. 
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No. Study 
 
Country Setting Study Design Population Duration  Sample Size Prevalence Rate 
of Bleeding ADR 
(%) 
Prevalence Rate of 
Non-Bleeding 
ADR (%) 
Reported 
Severe Cas-
es (%) 
Main Findings Other 
10. Ho et al. 
(2014) 
China Hospital Prospective 
cohort 
Patients with 
AF 
16 
months 
467 16.8% (minor and 
major bleeding) 
45.6% (Dyspepsia, 
and other side 
effects)  
NR There is need to determine the high 
discontinuation rates (21.6%) for 
Dabigatran for stroke prevention in AF 
patients in China 
 
11. Hu et al. 
(2015) 
Taiwan Hospital Prospective 
cohort 
Patients with 
NVAF on 
dabigatran 
6 
months 
150 NR 11.3% NR Monitoring non-compliance is im-
portant to improve compliance of 
Dabigatran  
10.7% non-
compliant 
12. Beyer-
Westendorf et 
al. (2015) 
Germany Non-
interventional 
patient registry 
Prospective 
cohort 
Stroke pre-
vention in 
patients with 
AF 
17 
months 
2,500 2.3% in 100 pa-
tient years 
NR 25.8%/100 
patient 
years 
Dabigatran is effective and relatively 
safe in unselected patients in daily 
care.  
 
13. Chan et al. 
(2016) 
Taiwan Taiwan National 
Insurance Re-
search Database 
Prospective 
study 
Patients with 
AF 
8 
months 
19,853 HR (0.58; 
P<0.0001) 
HR (ischemic 
stroke, 0.62; 
P<0.0001); myo-
cardial infarction, 
0.67; P=0.0803) 
NR Dabigatran has a reduced risk of all-
hospitalised major bleeding events, 
ischemic stroke and myocardial infarc-
tion compared to Warfarin for Asian 
NVAF patients  
 
14. Gorst‐Rasmus
sen et al 
(2015) 
Denmark Nationwide da-
tabase 
Prospective 
cohort 
Patients with 
AF 
23 
months 
2,960 NR NR NR Determining the extent and form of 
Dabigatran non-adherence is im-
portant to inform patient education 
and improve adherence.  
76.8% adher-
ence after 1 
year 
15. Thorne et al. 
(2015) 
New Zea-
land 
Primary care 
practice 
Prospective 
cohort 
Patients on 
Dabigatran 
10 
months 
92 10% 17.4% NR High rates of Dabigatran discontinua-
tion (30%) associated with gastro-
intestinal complications. 
 
16. Martinez et al. 
(2016) 
UK Primary care 
practice database 
Prospective 
cohort 
Patients with 
AF  
22.8 
months 
27,514 1.4% NR NR There is a greater persistence for NO-
ACs (79.2%) than warfarin therapy and 
could lead to fewer cardio-embolic 
strokes.  
 
17. Monteagudo 
et al. (2015) 
UK Cerebrovascular 
disease unit 
Prospective Patient 
treated with 
Rivaroxaban 
15 
months 
89 6.58% NR 0.82% Rivaroxaban is safe and efficacious for 
the prevention of secondary AF. 
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We used the Critical Appraisal Skills Programme 
(CASP) to grade the overall strength of the evidence 
as high, moderate, low, or insufficient. Another as-
sessment was performed after data extraction. An in-
depth quality analysis was impractical because of the 
heterogeneity of the study designs. Quality criteria 
were applied and considered, including the rele-
vance of the study to the aims of the review, appro-
priateness of the study design for the research objec-
tive, sample size, participant allocation, and outcome 
assessment. 
RESULTS AND DISCUSSION 
Results 
After the titles had been critically examined to re-
move obviously irrelevant studies from those ob-
tained through an extensive literature search of rele-
vant electronic databases, we retrieved 3929 primary 
studies. After excluding all duplications, 3915 studies 
were selected out of which 15 were identified as be-
ing potentially relevant after reviewing the titles, 
abstracts, and full texts. A hand search of retrieved 
articles from the electronic database led to the identi-
fication of two additional articles. Therefore, the re-
viewers agreed on a final selection of 17 studies for 
inclusion. A flow chart of this process is presented in 
Figure 1. 
Eight retrospective cohort studies were conducted in 
four countries (the U.S., Denmark, New Zealand, and 
Sweden). The study duration ranged between 3 (Lee 
et al., 2013) and 32 (Forslund et al., 2016) months and 
the data collection method involved patients or na-
tional databases. The nine prospective cohort studies 
were conducted in seven (countries (the UK, the US, 
Denmark, New Zealand, China, Taiwan, and Ger-
many). The study duration ranged from 10 (Thorne 
et al., 2014) to 23 (Gorst‐Rasmussen et al., 2015) 
months and the sample sizes ranged from 150 (Hu et 
al., 2015) to 27,514 (Martinez et al., 2016) subjects. 
The data collection method involved electronic med-
ical record reviews (Donaldson and Norbeck, 2013; 
Lee et al., 2013; Cutler et al., 2014; Ho et al., 2014; 
Monteagudo et al., 2015; Martinez et al., 2016), elec-
tronic national database searches Larsen et al., 2013; 
Graham et al., 2014; Beyer-Westendorf et al., 2015; 
Chang et al., 2015; Gorst‐Rasmussen et al., 2015; Hu 
et al., 2015; Chan et al., 2016; Forslund et al., 2016; 
Nishtala et al. 2016), questionnaires (Thorne et al., 
2014; Hu et al., 2015), and a reporting system (An-
dreica and Grissinger, 2015). The settings of these 
studies were in hospitals, primary care centres, or 
both. 
Types and Causes of Medicine-Related Problems Identified 
Across Studies 
Two studies compared the hazard ratio (HR) of the 
DOACs and warfarin and found that DOACs had no 
significant effect on excessive bleeding with HRs of 
0.60 (Larsen et al., 2013) and 0.45 (Nishtala et al., 
2016). One study (Graham et al., 2014) examined 
ADR bleeding-related events associated with 
dabigatran and found a 2.2% risk of bleeding. The 
persistence of DOAC therapy decreased from 88.2% 
in year 1 to 82.9% in year two of dabigatran use (For-
slund et al., 2016), and adherence was slightly differ-
ent between pharmacy-managed anticoagulant care 
(93.1%) and non-pharmacy care (88.3%) (Lee et al., 
2013). Medication errors associated with the oral an-
ticoagulants including warfarin and DOACs were 
831 incidents reported in 2014 by the Pennsylvania 
Patient Safety Advisory. The most common errors 
were drug omission (32.5%), other errors (prescrib-
ing, wrong patient, and inaccurate medication list-
ing) (18.5%), and wrong dose (11.7%) (Andreica and 
Grissinger, 2015). 
DOACs reduce the risk of intracranial bleeding and 
may decrease the overall risk of major bleeding 
events in patients with AF. In contrast, there is a pos-
sibility of an increased risk of gastrointestinal bleed-
ing associated with the use of DOACs (Miller et. al., 
2012). In the prospective studies, the reported ADR-
related bleeding events ranged between 2.3% (Beyer-
Westendorf et al., 2015) and 16.8% (Ho et al., 2014) of 
the surveyed population. The rate of non-compliance 
to dabigatran was 11.3% (Hu et al., 2015) and rates of 
adherence after one year was 76.8% 
(Gorst‐Rasmussen et al., 2015). In China, dabigatran 
had a high discontinuation rate of 17.4% associated 
with gastrointestinal complications (Thorne et al., 
2014). However, in the UK, there was a greater per-
sistence (72.9%) for DOAC therapy than there was 
for warfarin therapy (Martinez et al., 2016). The per-
sistence of DOAC therapy was 83%, and therapy 
commencement increased to 27% between 2011 and 
2014 (Martinez et al., 2016). In Taiwan, non-
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compliance to dabigatran therapy was 10.7%, and 
little attention was focused on non-compliance (Hu 
et al., 2015). In New Zealand, there were high rates of 
dabigatran therapy discontinuation (30% after 8 
months), which was attributed to increased gastroin-
testinal complications (Martinez et al., 2016). Severe 
cases were those in which hospitalization due to ma-
jor bleeding resulted in an increased requirement for 
treatment or caused permanent harm. Only one ret-
rospective study reported severe cases of ADR 
(3.14%) (Cutler et al., 2014). Among the examined 
prospective studies, two reported severe cases, with 
rates of 0.82% (Monteagudo et al., 2015) and 25.8% 
(Beyer-Westendorf et al., 2015). 
 
Fig. 1. Flow chart for identification of selected studies. 
Contributing Factors  
The factors that could contribute to the incidences of 
MRPs include old age, polypharmacy, sex, educa-
tion, immobilization, depression, and cohabitation 
(Al Hamid et al., 2013). The meta-analysis of Beijer 
(2002) showed that the probability of being hospital-
ized due to ADR-related problems is four times 
higher for elderly people than for younger people 
(16.6% vs. 4.1%). In this review only one study re-
ported old age as contributing factors to increased 
risk of gastrointestinal bleeding (Graham et al., 2014).   
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Discussion 
Identifying studies that investigated MRPs experi-
enced by patients with AF using DOACs was chal-
lenging. In this review, studies focused on the preva-
lence, categories, and cause and severity of MRPs 
among adult patients with AF using DOACs were 
critically reviewed. The findings of this review sug-
gest that no studies defined MRPs involving DOACs, 
and ADRs and ADEs were used interchangeably. 
Four of the retrospective studies investigated ADRs 
(Larsen et al., 2013; Graham et al., 2014; Chang et al., 
2015; Nishtala et al., 2016], one investigate medica-
tion errors (Andreica and Grissinger, 2015), one in-
vestigated persistence (Forslund et al., 2016), and two 
investigated adherence (Lee et al., 2013; Cutler et al., 
2014). Furthermore, six prospective studies investi-
gate ADRs (Donaldson and Norbeck, 2013; Ho et al., 
2014; Thorne et al., 2014; Beyer-Westendorf et al., 
2015; Monteagudo et al., 2015; Chan et al., 2016), one 
study investigate persistence (Martinez et al., 2016), 
and two investigate adherence (Gorst‐Rasmussen et 
al., 2015; Hu et al., 2015). In addition, most of the 
studies investigated dabigatran, which was the first 
DOAC available in the market. In the analysis of ad-
herence, all the studies examined patient adherence 
to dabigatran. The findings of this review for ADR-
related bleeding ranged from 2.3 to 16.8%, whereas 
in the RCTs, the prevalence of ADR-related bleeding 
with the use of DOACs for preventing stroke and 
systemic embolism in patients with AF ranged from 
1.5% (Holster et al., 2013) to 4.9% (Dentali et al., 
2012), which was the percentage of the total popula-
tion studied. Three meta-analyses compared the safe-
ty profile of ADR-related bleeding events between 
the DOACs and warfarin in patients with AF and 
found that the DOACs had a better safety profile 
with an odds ratio (OR) of 0.49 (Lega et al., 2014), 
0.33 (Chan et al., 2016) and 0.58 (Caldeira et al., 
2015a) for intracranial haemorrhage, gastrointestinal 
bleeding, and all hospitalised major bleeding events. 
The efficacy between the DOACs was similar (OR: 
0.79, apixaban; 0.77, dabigatran; and 0.86, rivaroxa-
ban), but they differed in risk and safety profile. In 
patients with renal failure, there was an increase in 
bleeding events with dabigatran compared to riva-
roxaban and apixaban (Lega et al., 2014). The DOACs 
also showed the same efficacy and safety profiles in 
the treatment of both male (5.55%) and female (8.4%) 
patients with AF (Dentali et al., 2015). The DOACs 
do not cause excessive bleeding in patients > 75 years 
old compared to the effect of conventional treatments 
(DOACs 6.5% vs. warfarin 7.1%) (Sardar et al., 2014).  
Three meta-analyses studied non-ADR-related bleed-
ing events of DOACs. The DOACs do not show an 
increased risk of causing drug-induced liver injury 
(0.22% of the study population), and they had a low-
er risk of substantial intraocular bleeding (0.04%) 
than warfarin did; however, they showed a similar 
risk of renal failure to that of warfarin (OR, 0.96)( 
Caldeira et al. 2014, Caldeira et al. 2015a, Caldeira et 
al. 2015b). In this review, the prevalence of non-
ADR-related bleeding events ranged from 45.6%-
2.7%. Only one meta-analysis investigated discontin-
uation of DOACs therapy and found the rate (6.08%) 
was similar to that of conventional drugs used in the 
treatment of thromboembolism and the prevention of 
stroke in patients with AF (Chatterjee et al., 2014).    
Summary of Study Strengths and Limitations 
To the best of our knowledge, this study is the first 
systematic review of MRPs in adult patients with AF 
using DOACs. Two independent reviewers investi-
gated the data retrieved from previous studies to 
avoid bias. Moreover, the inclusion and exclusion 
criteria used met the research aim. Some of the study 
limitations are that the included studies in this re-
view varied in sample sizes that were in the range of 
68-20,636 subjects, and they had different settings 
and data collection methods. The results are also lim-
ited by the length of follow-up, which was from 3-27 
months. There were countries other than the US, Eu-
rope, UK, and Asia, which showed differences in 
medicine used. An additional limitation the use of 
different terms to described the MRPs such as ADR, 
ADE, medication errors, and adherence. However, 
this review clearly shows that articles on MRPs expe-
rienced by patients with AF using DOACs are lim-
ited. Therefore, more studies examining medicine-
related problems in patients with AF using DOACs 
and the contributing factors in clinical settings are 
needed to ensure patient outcomes are effectively 
improved and risk to patients are reduced. 
 
 
  https://doi.org/10.5920/bjpharm.2017.07  
Alewairdhi et al (2017) BJPharm 2(1), 3-13  11 
CONCLUSIONS 
There have been no systematic investigations of 
MRPs in adult patients with AF using DOACs in 
clinical practice. This review indicates that DOACs 
have a favourable risk/safety profile for treatment of 
patients with AF, given the reduced risk of ADR-
related major and minor bleeding events; however, 
there was a variation in the measured risk among the 
studies. In addition, 12 of the 17 studies only investi-
gated dabigatran. Non-bleeding ADRs were reported 
in five studies with limited specification. The discon-
tinuation rates for the dabigatran therapy showed 
mixed findings. Although they were similar to those 
for warfarin, the discontinuation rates for dabigatran 
were higher in China and New Zealand than in other 
countries because of gastrointestinal complications. 
Persistence rates for dabigatran therapy remained 
high (> 80%) but slightly decreased between the first 
and the second year (88.2–82.9%). Medication errors 
associated with oral anticoagulants including DO-
ACs were relatively frequent. More attention should 
be focused to adherence, persistence, monitoring, 
and follow-up for all DOAC therapy to reduce the 
rate of ADR-related bleeding events. Encouraging 
continuous ADR reporting is important to improve 
patient safety.  
One recommendation for future work is to compare 
oral anticoagulants in the clinical practice setting on 
the basis of specific outcome measures. In addition, 
head-to-head comparisons of different types of DO-
ACs are needed. In this manner, clinical practice will 
be informed with quality information regarding the 
safety of DOACs. Future combination of qualitative 
and quantitative studies with such research ques-
tions will enable the formulation of clinically rele-
vant policies and guidelines. Therefore, further stud-
ies are needed to further examine the medicine-
related problems of DOACs in patients with AF. 
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